NOTE. This is the first time I have seen this this happening. I have found this new article, and…before I found this article, I have found a phase 3 clinical trial that is already applying these findings! Maybe a positive sign? Or an old article rebranded? Anyway look also for my other post about the clinical trial
The research discussed in the sources focuses on the role of the enzyme EZH2 in the development of castration-resistant prostate cancer (CRPC). Scientists have discovered that when the protein kinase PKCλ/ι is absent in prostate cancer cells, EZH2 promotes aggressive tumor growth even when androgen receptor inhibitors are present. Typically, PKCλ/ι regulates EZH2 activity, but in its absence, an alternative form of EZH2 develops and drives rapid protein production and activates growth factors that contribute to cancer progression. Researchers believe that inhibiting this alternative function of EZH2 or targeting the TGF-β pathway could potentially reverse resistance to treatment in CRPC and not only, it could make CRPC sensitive to immunotherapy.
